Login / Signup

A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer.

Esteban TerzoShruti A ApteSimran PadhyeSaleh RashedWesley AustinMichael CaponegroAnupama ReddyShuhao ShiChristy WangRoger B ClarkDavid SidranskyVijay ModurVasudeo Badarinarayana
Published in: Cancer research communications (2023)
This study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors. The colorectal cancer CMS2 subtype, with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome modulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.
Keyphrases
  • papillary thyroid
  • squamous cell
  • climate change
  • signaling pathway
  • childhood cancer
  • transcription factor
  • cancer therapy
  • drug delivery
  • quality control